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Studies were undertaken on a highly mstastatic hamster fibrosarcoma cell line with a view to assessing whether cells entering into npoptosis. 
measured by counting the number of transglutaminase mediated etergent insoluble cnvclopcs, has any synchrony with a particular phase of the 
cell cycle. A double exposure of thymidine was used to block cells in early S-phase. Flo\vcytomctry in combination with ~Hlthymidinc incorporation 
into DNA was used to assess the d gree of synchrony and prcgrcssion lhrough the different phases ofccll cycle. The apoplolic index was found 
to be at its maximum in mid-S-phase. Measurement of transglutaminasc a livity in each phase of the cell cycle indicated that the sprcilic activity 
was also at its greatest during mid S-phase. The level of enzyme was relatively unchanged throughout he cell cycle indicating that the regulation 
of transglutaminasc a tivity occurs primarily through effects on catalytic activity rather than enzyme synthesis. 
Cell cycle: Tissue transgluteminasc; Apoptosis 
1. INTRODUCTION 
Programmed cell death, or apoptosis, is a process 
whereby cells die in response to a specific physiological 
signal. Apoptosis was first described in 1972 [I] and is 
now known to play a role in a number of biological 
processes including embryogenesis tissue remodeling 
and tumour regression [2]. Morphologically the process 
is characterised by cells undergoing both nuclear and 
cytoplasmic ondensation resulting in the formation of 
apoptotic bodies which are r .zza!!y rapidly phagocy 
tosed by neighbouring cells or by macrophages. Chro- 
matin condensation is thought o result from activation 
of an endogenous Ca’+ and Mg” dependent endonu- 
clease [3], although in some systems this process is not 
always apparent [4]. Apoptotic body formation is 
thought to require increased expression of tissue 
transglutaminase [5,6]. Both those enzymes carry out 
irreversible reactions on ce’llular molecules. Transglu- 
taminases (EC 2.3.2.13) catalyse a Ca’+-dependent acyl 
transfer eaction between the r_carboxamide group of 
a peptide bound glutamine residue and the c-amine 
group of peptide-bound lysine resulting in the produc- 
tion of highly crosslinked protein aggregates [7]. Three 
forms of transglutaminase each with its own distinct 
gene have been well characterized: the plasma factor 
XIII, the keratinocyte nzyme, and the tissue transglu- 
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taminase [8,9]. While the physiological role of the first 
two enzymes is well understood, the role of the tissue 
enzyme is still unknown. Recent studies uggest he cy 
tosolic form of the tissue enzyme is involved in the 
physiological cell death programme where increased ex- 
pression of the enzyme leads to the formation of a 
highly crosslinked etergent insoluble protein shell [IO]. 
Such a role is comparable to that of the keratinocyte 
transglutaminase where activation of this enzyme leads 
to the assembly of the insoluble cornified envelope be- 
neath the plasma membrane of the terminally differenti- 
ating keratinocyte [l 11. Transglutaminase mediated ap- 
optotic body formation provides a potential method for 
measurement ofcells undergoing apoptosis in particular 
in a cell population where the apoptotic index is very 
low. For example, in malignant cells there is now in- 
creasing evidence to suggest hat aberrant apoptosis 
leading to an imbalance between cell proliferation and 
cell death may be an important feature in the develop- 
ment of the metastatic phenotype [10,12]. Studies with 
a malignant hamster fibrosarcoma cell line have indi- 
cated a direct correlation between transglutaminase ac- 
tivity and the spontaneous levels of apoptosis occurring 
in these cells [lo], and an indirect correlation between 
transglutaminase activity and metastatic potential 
[10,13,143. Of importance in this scenario is whether 
apoptosis can take place at any point in the cell cycle 
or whether it is necessary for cells to leave the cell cycle 
and become quiescent before the apoptotic programme 
can begin. This fundamental question is important in 
the overall understanding of apoptosis itself and in the 
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development of new anticancer therapies designed to 
induce apoptosis. 
In order to answer this question we have measured 
apoptotic body formation and transglutaminase activ- 
ity in the different phases of the cell cycle of a highly 
metnstatic hamster fibrosarcoma cell line. 
2. EXPERIMENTAL 
A highly melostatic hamster fibrosarcoma cell line (Met B) was 
grown in supplemented DMEM (Dulbecco’s modified essential mc- 
dium) as previously described [IO]. Cell numbers were monitored by 
direct counting using a hncmatocytomctcr. 
Exponentially growing cells (approximalcly I.5 x 105/ml) were 
treated for I6 h with 2 mM thymidinc. Cells were then washed, resus- 
pended in a drug-fne medium for 8 h and subsequently treated with 
the same amount of thymidine for an additional I6 h. In another 
cxperimcnt, exponentially growing cells were treated with a single dose 
of4 mM thymidina for 16 h. The cytotoxic effect of thymidine was 
monitored by Trypan blue exclusion method. 
The degree of synchrony was assessed at various times following the 
rclcase of the thymidine blockage by two different methods. 
2. I. fnrorpowriott oJ’ [JH]rlt,wticIinc (33 nG/tttrnol) ittto DNA 
Cells wrc incubated at 37°C with 2&i ofradiolabellcd thymidine 
for 30 min. Cells wcrc washed with I ml of 5% (w/v) TCA 10 remove 
the acid-soluble fraction. The precipitate was washed twice with S% 
TCA and solubilised in 0.5 ml of 1 M KOH. 0.2 ml portions of the 
alkaline extract were measured for radioactivity in liquid scintillation 
cocktail (Packard Inslrumcnts) using a Packard A300 CD Spectro- 
photomctcr. 
2.2. Flow cyrottwwJ~ 
Cells (approximately I x lob) were harvested at vurious times fol- 
lowing the release of thymidinc, then washed with PBS and stained 
with nucleic acid intercalating dye, propidium iodide (PI), using a 
Cycle Test staining Kit (Becton Dickinson). Briefly, cells wcrc incu- 
bated with trypsin, in stabilising buffer; Ihe resulting nuclei were then 
stained with PI following treatment with trypsin inhibitor and RNase. 
Flow cytometric analysis was carried out on an ‘Orthocytc bench top 
cytometer’ equipped with a mercury/xenon arc lamp. At least IO’ 
nuclei were measured using a stnndardised (stored) analysis protocol, 
with B slow flow rate of 5 ,&min. Histograms wcrc stored and files 
reanalysed using the MULTICYCLE DNA analysis package. Sam- 
ples representing a GO/G1 peak with cocllicicnt of variation (CV) 
greater than IO, were excluded from this study. 
‘Transglutaminasc a tivity was measured incell homogenates by the 
Co’+-dependent i corporation of [‘%Z]putrescinc i to NJ-dimeth- 
ylcasein [I I]. Activity is expressed as units (1 unit being equivalent to 
I nmol of putrescinc incorporabzd per h under the conditions of the 
assay). Protein concentration was determined by Lowry method [IG]. 
Trztnsglutaminase antigen was measured by a quantitative sandwich 
ELISA [17]. 
For assessment of the apoptotic index, detergent-insoluble apo- 
ptotic envelopes were isolated from synchronized cells [l?]. Apoptotic 
index is expressed as the number of apoptotic envelopes obtained from 
I06 cells. 
3. RESULTS AND DISCUSSION 
Both aphidicolin (DNA polymerass a inhibitor) and 
thymidine (thymidine kinase inhibitor) were used ini- 
tially in order to establish which drug would produce 
satisfactory synchrony in the hamster fibrosarcoma 
(Met B). The most efficient cell synchrony was obtained 
Time foIlowing &ug release Ihrs) 
I. DNA synthesis and cell replicaiion in ihymidine synchronised 
cells. Cells wcrc synchroniscd with 2 mM thymidinc 1s described under 
cxpcrimentals. (0) DNA synthesis was assessed by following the incor- 
poration of [‘Hlthymidinc intoTCA precipitablecomponcnts.(+)Ccll 
numbers were dctertnined by direct microscopic ounting using a 
hacmocytometer. 
by exposing cells to a double block with 2 mM thymid- 
ine. During the first exposure to thymidine, cells en- 
gaged in DNA synthesis are blocked in S-phase, while 
cells in other phases continue growth and accumulate 
at Gl/early S-phase. On removal of the drug, the whole 
population passes through the cell cycle into Gl-phase, 
which takes about 6-S h. Further exposure of cells to 
thymidine at this stage for 14-16 h results in blockage 
of the cell population at early S-phase. This protocol 
resulted in synchronous population of Met B cells which 
produced satisfactory synchrony (see below). Using 
[3H]thymidine incorporated into DNA as a marker of 
DNA synthesis, Fig. 1 shows that following imposition 
of the drug (0 h) complete inhibition of DNA synthesis 
is obtained. However, on removal of the drug cells move 
through the cell cycle and DNA synthesis rapidly re- 
sumes reaching a maximum by 2-3 h, then decreases to 
minimal level between 4 and 6 h as the cells undergo 
mitosis and divide as indicated by the increase in cell 
number. Cell synchrony was also assessed at various 
times following exposure to thymidine by flow cytom- 
etry. DNA histograms (Fig. 2) indicate that exponen- 
tially growing cells are blocked in early S-phase and 
generally constitute greater than 85% of the cell popula- 
tion. By G h following the removal of drug, cells llave 
passed through GUM and into GO/G1 phase by 8 h. 
This result confirms the data shown in Fig. 1 and shows 
that this highly metastatic hamster fibrosarcoma cell 
line takes a period of approximately 8 h to progress 
through cell cycle before synchrony is lost. 
Measurement of transglutaminase activity (U/mg 
protein) in the different phase of cell cycle following 
removal of thymidine indicated little change in activity 
up to G h (G2/M-phase). After this time, a slight but 
significant increase was detected as the cells progressed 
from G2/M to GO/G1 and finally to loss of synchrony 
(Fig, 3AJ In contrast, when transgiuiaminase activity 
is expressed per ng of enzyme protein, the specific activ- 
ity was found to show a significant increase after 2-3 h 
175 
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DNA content 
L 
DNA content 
Fig. 2. DNA histograms from thymidine-synchranised M t 0 cells. Al 
the time indicated in each figure, cells were released from thymidine 
blockade, stained with propidium iodide and analysed by flow cytom- 
etry as described under experimental. NS, non-synchroniscd cells; 
dotted, GO/G I-phase; hatched, Spphase; and black, G2/M-phase. 
corresponding to mid S-phase of the cell cycle (Fig. 3I3). 
Measurement of enzyme antigen (Fig. 3C) indicated this 
increase was not due to altered expression of the enzyme 
but more likely due to a direct effect on the catalytic 
activity of the enzyme itself. 
Measurement of apoptosis in the synchronised Met 
B cell line was undertaken by counting the number of 
transglutaminase-mediated detergent-insoluble apop- 
totic envelopes resulting from a fixed number of cells. 
However, before using this technique, it was necessary 
to demonstrate that in this hamster fibrosarcoma, iso- 
lated detergent insoluble envelopes are indeed derived 
from cells undergoing morphological changes typical of 
apoptosis. Non-synchronised Met I3 cells were therefore 
first separated into enriched apoptotic and non-apop- 
totic population using fractionation on a Percoll step- 
density gradient [181. Examination of these two popula- 
tions by phase microscopy indicated the dense apop- 
totic population to contain a high percentage of cells 
with obvious surface blebbing typical of apoptosis (Fig. 
Time followlng drug release (hrsl 
Fig. 3. Transglutaminase activity W/mg protein (A), Ulng enzyme 
(a)), transglutaminasc level (C) and apoptotic index (D) in synchron- 
ised Met B cells compared to non-synchronised cells (NSYN). The 
results represent the average data from 5 experiments. 
4). Isolation of detergent insoluble envelopes from the 
enriched apoptotic and the non-apoptotic populations 
demonstrated that greater than 90% of the envelopes 
were present in the enriched apoptotic cell population. 
Measurement of the number of apoptotic envelopes in 
the synchronised Met B ceils indicated that by far the 
greatest level of apoptosis was found in mid S-phase 
although spontaneous apoptosis was detectable in all 
phases of the cell cycle (Fig. 3D). To demonstrate that 
this increase in apoptosis was not due to the toxicity of 
the thymidine, cells were also blocked in GO/G1 using 
one dose of 4 mM thymidine (Fig. 5). Measurement of 
176 
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Fig. 4. Phase contrast appearance (x400) of enriched apoptotic Met 
B cells following fractionation on a pcrcoll step-density gradient [la]. 
A, apoptotic ell; N. non-apoptotic cell; and M, cell undergoing mito- 
sis. 
apoptosis in these cells following removal of the drug 
indicated that the maximum apoptotic index was not 
found at 2 h that might be indicative of thymidinc tox- 
icity. Instead it could be shown that the greatest number 
of apoptotic envelopes once again correlated with the 
mid S-phase of the cell cycle where incorporation of 
[3H]thymidine was at its maximum which in this exper- 
iment occurred 4 h after removal of the drug (Fig. 5). 
Our results therefore indicate that in a rapidly prolif- 
erating fibrosarcoma cell line, cells undergoing sponta- 
neous apoptosis are more likely to enter into the apop- 
totic programme at a specific phase of the cell cycle 
corresponding to that of mid S-phase. It has been sug- 
gested that failure of damaged cells to successfully pass 
through cell cycle check point such as G2/M may lead 
to apoptosis [19]. Our data indicates that this check 
point is likely to be in mid S-phase rather than CUM. 
In keeping with this observation is the tinding that 
agents of pharmacological nature induce death selec- 
tively in S-phase [20]. Of particular interest is the ob- 
served increase in the specific activity of transglutami- 
nase which parallels the maximum rate of apoptosis 
observed uring mid S-phase. Although an increase in
the expression of the enzyme in the apoptotic cell has 
been demonstrated [6,21], no previous data has indi- 
cated a change in the specific activity of the enzyme 
which is indicative of a direct effect on the catalytic 
activity of the enzyme. The recent finding that phospho- 
rylation of the brain transglutaminase l ads to an in- 
Tbne following drug release Ws) 
Fig. 5. DNA synthesis (line) and apoptotic index (bar) in Met B c-ells ynchroniscd with one dose of4 mM thymidinc. The inserl shows the DNA 
histogram of cells stained with prop&m iodide and analyscd by flow cytometry at 0 h following removal of dmg. 
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crease it? the enzymes aflinity to calmodulin is particu- 
larly intriguing in this respect [22]. 
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